NewTimeSpace News: TRANSTHERA-B announced that its self-developed Class 1 new drug Jientai (tiengotinib tablets) has received conditional NMPA approval for marketing, for advanced cholangiocarcinoma with FGFR2 fusions or rearrangements in patients previously treated with systemic therapy and FGFR inhibitors; the Phase II pivotal study showed an ORR of 28.0% and median overall survival of 20.7 months; the drug has received US FDA Orphan Drug Designation and Fast Track Designation and European EMA Orphan Drug Designation, and this is its first indication approved in China.
NewTimeSpace News: TOP EDUCATION announced that on 5 August it became aware of a threat actor claiming to possess and intend to sell records allegedly relating to students on an underground forum; the Group has immediately launched an investigation and notified the Tertiary Education Quality and Standards Agency and the Australian Cyber Security Centre; the suspected incident has not caused material disruption to the Group's operations to date, and the Group will take appropriate actions as the investigation progresses.
NewTimeSpace News: HENGRUI PHARMA announced that the third indication of its subsidiary Suzhou Shengdiya's trastuzumab rezetecan for injection has been approved for marketing, for adult patients with HER2-positive colorectal cancer who failed oxaliplatin, fluorouracil and irinotecan, making it the first anti-HER2 product approved for colorectal cancer in China; the self-developed HER2 ADC has its pivotal Phase III data presented at the 2026 ASCO Annual Meeting, 11 indications included in the Breakthrough Therapy Designation list, and cumulative R&D investment of approximately RMB 2.144 billion.
NewTimeSpace News: HENGRUI PHARMA announced that the NMPA has approved a fifth indication for its self-developed Class 1 innovative drug ivarmacitinib sulfate tablets, for adult patients with active non-radiographic axial spondyloarthritis, achieving full-disease-spectrum oral targeted management coverage of axial spondyloarthritis; the product is a highly selective JAK1 inhibitor with pivotal Phase III data presented at the 2026 EULAR Annual Meeting, and cumulative R&D investment of approximately RMB 1.235 billion.
NewTimeSpace News: ENVISION GREEN announced that its indirect wholly-owned subsidiary Shanghai Youfu Cloud Computing intends to purchase high-performance servers for RMB 1.2884 billion (approximately HKD 1.4885 billion, inclusive of tax) from Shanghai Shunquan Technology to support the Group's cloud computing and intelligent computing capabilities; as the applicable percentage ratios exceed 25% but are below 100%, the transaction constitutes a major transaction; written approval from shareholders holding approximately 50.62% has been obtained, and no general meeting will be convened.
NewTimeSpace News: NETJOY announced that its independent internal control follow-up review has been completed; all remedial measures recommended in the internal control review report have been implemented and are operating, except for procurement acceptance processes (not applicable as the Group ended its new short-drama purchase business in June) and inventory transfers (no samples available as the Group operates a single warehouse), with the Board affirming the rectification results; the Company's shares have been suspended since 1 April 2025 and will remain suspended until all resumption guidance is met.
NewTimeSpace News: August 06, 2026, PACIFIC BASIN(02343.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at USD 1.11 billion, increased by 8.52% YoY.
NewTimeSpace News: August 06, 2026, TOM GROUP(02383.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at HKD 335.25 million, decreased by 1.02% YoY.
NewTimeSpace News: CITIC SEC announced the completion of the issue of 803,725,383 new H shares to CITIC Financial Holdings on 6 August 2026 at an issue price of HKD 23.13 per share, with total proceeds of RMB 16 billion and net proceeds of approximately HKD 18.413 billion; following completion, CITIC Financial Holdings holds approximately 23.96% of the Company, with the new H shares subject to a 48-month lock-up; all net proceeds will be retained overseas for international business development, including capital injection of up to RMB 16 billion into CITIC Securities International.
NewTimeSpace News: HANSOH PHARMA announced that HS-10582 tablets, a Class 1 new drug independently developed by the Group, has received the Drug Clinical Trial Approval Notice from the NMPA, intended for clinical trials for the treatment of primary hypercholesterolemia and mixed dyslipidemia in adults, marking new progress in its R&D.
NewTimeSpace News: HAOHAI BIOTEC announced that its controlling subsidiary Saimaishi has obtained an NMPA medical device registration certificate for its trifocal toric IOL (valid until 3 August 2031), which passed the special review procedure for innovative medical devices and is the first domestically approved trifocal toric IOL in China; the Company has formed a high-end refractive IOL product matrix covering monofocal through multifocal toric correction; as the product has not yet generated sales, it will not materially affect near-term results.
NewTimeSpace News: TRIUMPH NEW EN announced that it has received a regulatory warning letter from the CSRC Henan Bureau for untimely disclosure, as cumulative litigation and arbitration over 12 months reached RMB 333 million (10.73% of the absolute value of the latest audited net assets); Chairman Mr. Xie Jun, General Manager Mr. Chen Peng and Board Secretary Mr. Chen Hongzhao were held primarily responsible for failing to perform duties diligently; the Company must submit a written rectification report within 15 working days.
NewTimeSpace News: C FIN SERVICES announced that its wholly-owned subsidiary Shenzhen Lingda Small Loans granted a loan of RMB 8.3 million with a six-month term to Customer GL at an annual interest rate of 12%, secured by a residential property mortgage in Nanshan, Shenzhen (valued at approximately RMB 10.461 million); as the applicable percentage ratio exceeds 5% but is below 25%, the loan constitutes a discloseable transaction.
NewTimeSpace News: MEDIA CHINESE(00685.HK) announced the completion of the proposed disposal of a property in Canada on 6 August 2026; upon completion, the vendor is no longer the owner of the property; the disposal constitutes a discloseable transaction.
NewTimeSpace News: Linmon Media Limited announced on 6 August that it expects net profit, net profit attributable to owners and adjusted net profit for the six months ended 30 June 2026 to range from approximately RMB20 million to RMB40 million.
NewTimeSpace News: S HARBOURHOLD(01663.HK) announced that chairman and major shareholder Mr. Wang Linbing purchased 9,446,000 ordinary shares of the Company in the open market on 6 August 2026, at an average price of approximately HKD 0.052 per share and a highest price of HKD 0.055 per share; Mr. Wang is the husband of major shareholder Ms. Chen Xiangling and the father of executive director Mr. Wang Lei.
